Shanghai Pharmaceuticals Ownership

601607 Stock   21.30  0.45  2.07%   
Shanghai Pharmaceuticals shows a total of 2.79 Billion outstanding shares. Shanghai Pharmaceuticals has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.61 % of Shanghai Pharmaceuticals outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Shanghai Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Shanghai Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
The current year's Dividends Paid is expected to grow to about 4.2 B. The current year's Net Income Applicable To Common Shares is expected to grow to about 6.2 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 3.4 B.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Shanghai Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Shanghai Stock Ownership Analysis

About 66.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.14. In the past many companies with similar price-to-book ratios have beat the market. Shanghai Pharmaceuticals last dividend was issued on the 24th of September 2024. The entity had 1.2:1 split on the 16th of August 2007. For more info on Shanghai Pharmaceuticals Holding please contact the company at 86 21 6373 0908 or go to https://www.sphchina.com.

Shanghai Pharmaceuticals Outstanding Bonds

Shanghai Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Shanghai Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Shanghai bonds can be classified according to their maturity, which is the date when Shanghai Pharmaceuticals Holding has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.